Profile data is unavailable for this security.
About the company
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.
- Revenue in USD (TTM)249.94m
- Net income in USD-153.93m
- Incorporated2001
- Employees329.00
- LocationArrowhead Pharmaceuticals Inc177 E Colorado Blvd, Suite 700PASADENA 91105United StatesUSA
- Phone+1 (626) 696-4702
- Fax+1 (626) 304-3401
- Websitehttps://arrowheadpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | 230.49m | -701.64m | 4.07bn | 580.00 | -- | 5.67 | -- | 18.39 | -11.87 | -11.87 | 3.90 | 12.53 | 0.1669 | 0.841 | 6.71 | 465,630.30 | -50.82 | -23.88 | -56.65 | -26.44 | 90.76 | -- | -304.41 | -96.06 | 5.77 | -- | 0.00 | -- | -77.31 | 45.34 | -305.20 | -- | 5.59 | -- |
| Alkermes Plc | 1.17bn | -94.15m | 4.20bn | 2.21k | -- | 3.89 | -- | 3.59 | -0.579 | -0.579 | 7.22 | 6.59 | 0.6025 | 1.49 | 4.13 | 530,695.60 | -4.83 | -6.82 | -6.13 | -8.47 | 81.53 | 83.51 | -8.02 | -11.73 | 2.03 | -11.92 | 0.2139 | -- | 13.00 | 9.50 | 56.55 | -- | -8.49 | -- |
| Beam Therapeutics Inc | 76.92m | -233.99m | 4.28bn | 341.00 | -- | 5.78 | -- | 60.05 | -3.41 | -3.41 | 1.13 | 11.38 | 0.0666 | -- | 3.08 | 225,560.10 | -20.25 | -- | -23.75 | -- | -- | -- | -304.21 | -- | -- | -- | 0.0052 | -- | 215,916.70 | -- | -89.23 | -- | -- | -- |
| Global Blood Therapeutics Inc | 234.86m | -322.46m | 4.49bn | 457.00 | -- | 37.99 | -- | 19.20 | -5.00 | -5.00 | 3.64 | 1.76 | 0.3162 | 0.0782 | 9.53 | 513,919.00 | -43.42 | -36.17 | -48.87 | -39.55 | 98.10 | -- | -137.30 | -345.73 | 6.17 | -13.41 | 0.831 | -- | 57.31 | -- | -22.43 | -- | 19.05 | -- |
| Mirati Therapeutics Inc | 78.16m | -644.51m | 4.57bn | 413.00 | -- | 4.15 | -- | 59.09 | -11.85 | -11.85 | 1.45 | 20.00 | 0.0593 | -- | 2.28 | 189,256.70 | -48.91 | -42.36 | -55.19 | -45.89 | -- | -- | -824.57 | -1,299.08 | -- | -- | 0.00 | -- | 438.08 | -- | -62.54 | -- | 118.65 | -- |
| Intellia Therapeutics Inc | 45.34m | -400.43m | 4.59bn | 485.00 | -- | 5.74 | -- | 111.55 | -5.36 | -5.36 | 0.6072 | 11.59 | 0.0509 | -- | 18.71 | 93,484.54 | -44.92 | -25.86 | -50.53 | -28.70 | -- | -- | -883.17 | -343.23 | -- | -75.56 | 0.00 | -- | -43.01 | 14.94 | -99.58 | -- | 15.65 | -- |
| Denali Therapeutics Inc | 112.42m | -283.86m | 4.61bn | 395.00 | -- | 5.37 | -- | 42.28 | -2.32 | -2.32 | 0.9185 | 7.18 | 0.0802 | -- | 13.12 | 295,842.10 | -20.26 | -13.07 | -23.63 | -14.30 | -- | -- | -252.50 | -100.25 | -- | -- | 0.00 | -- | -85.50 | -- | -508.49 | -- | 6.74 | -- |
| Azenta Inc | 554.87m | -28.37m | 4.79bn | 2.90k | -- | 1.35 | 171.33 | 8.37 | -0.3814 | 29.03 | 7.42 | 45.71 | 0.2023 | 2.47 | 2.63 | 191,334.50 | -1.03 | 0.6373 | -1.14 | 0.764 | 47.51 | 41.42 | -5.11 | 1.39 | 12.79 | -- | 0.00 | 369.16 | 32.21 | 3.43 | -9.51 | -- | 32.67 | 0.00 |
| Arrowhead Pharmaceuticals Inc | 249.94m | -153.93m | 4.81bn | 329.00 | -- | 10.94 | -- | 19.89 | -1.48 | -1.48 | 2.37 | 4.29 | 0.3362 | -- | 549.32 | 759,693.00 | -20.71 | -16.34 | -26.94 | -19.63 | -- | -- | -61.59 | -55.64 | -- | -- | 0.00 | -- | 57.16 | 287.47 | -66.58 | -- | 43.59 | -- |
| Natera Inc | 723.48m | -575.58m | 4.93bn | 2.67k | -- | 12.05 | -- | 7.41 | -6.07 | -6.07 | 7.62 | 4.59 | 0.7548 | 13.18 | 4.69 | 270,965.20 | -60.05 | -40.13 | -78.45 | -55.58 | 46.38 | 43.84 | -79.56 | -61.14 | 3.46 | -67.91 | 0.4269 | -- | 59.97 | 24.10 | -105.32 | -- | 16.47 | -- |
| Cytokinetics, Inc. | 151.15m | -215.92m | 4.94bn | 253.00 | -- | 40.67 | -- | 32.85 | -2.59 | -2.59 | 1.80 | 1.30 | 0.2263 | -- | 64.68 | 597,442.70 | -32.32 | -38.05 | -35.77 | -41.80 | -- | -- | -142.85 | -352.73 | -- | -5.26 | 0.6416 | -- | 26.15 | -7.92 | -69.15 | -- | 98.25 | -- |
| Guardant Health Inc | 408.13m | -551.10m | 5.00bn | 1.37k | -- | 17.00 | -- | 13.29 | -5.41 | -5.41 | 4.01 | 3.12 | 0.1969 | 3.08 | 5.48 | 297,254.20 | -25.69 | -16.27 | -27.87 | -17.80 | 67.43 | 64.51 | -130.47 | -85.34 | 5.83 | -- | 0.7807 | -- | 30.32 | 71.41 | -59.85 | -- | 111.67 | -- |
| 10X Genomics Inc | 497.93m | -142.49m | 5.09bn | 1.24k | -- | 6.82 | -- | 10.69 | -1.26 | -1.26 | 4.43 | 6.88 | 0.5032 | 1.84 | 7.33 | 401,882.20 | -14.40 | -- | -16.30 | -- | 78.85 | -- | -28.62 | -- | 5.05 | -- | 0.00 | -- | 64.13 | -- | 89.27 | -- | -- | -- |
| Medpace Holdings Inc | 1.29bn | 209.02m | 5.24bn | 4.80k | 30.67 | 19.33 | 23.74 | 4.26 | 5.76 | 5.76 | 35.38 | 9.14 | 0.9237 | -- | 6.64 | 285,838.40 | 15.03 | 9.31 | 29.20 | 12.86 | 28.98 | 30.54 | 16.27 | 13.20 | -- | 417.58 | 0.4685 | -- | 23.38 | 22.06 | 25.16 | 68.40 | 15.87 | -- |
| Intra-Cellular Therapies Inc | 138.45m | -321.36m | 5.31bn | 512.00 | -- | 7.73 | -- | 40.32 | -3.69 | -3.69 | 1.58 | 7.65 | 0.1926 | 0.7529 | 4.45 | 270,416.30 | -44.71 | -40.81 | -48.82 | -43.86 | 91.08 | -- | -232.11 | -853.75 | 10.82 | -- | 0.00 | -- | 267.35 | 202.53 | -25.16 | -- | 46.09 | -- |
Data as of Aug 18 2022. Currency figures normalised to Arrowhead Pharmaceuticals Inc's reporting currency: US Dollar USD
37.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2022 | 11.12m | 10.52% |
| The Vanguard Group, Inc.as of 30 Jun 2022 | 9.80m | 9.27% |
| SSgA Funds Management, Inc.as of 31 Mar 2022 | 4.68m | 4.43% |
| AllianceBernstein LPas of 31 Mar 2022 | 2.76m | 2.61% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2022 | 2.74m | 2.59% |
| Invesco Advisers, Inc.as of 31 Mar 2022 | 2.01m | 1.90% |
| Geode Capital Management LLCas of 30 Jun 2022 | 1.85m | 1.75% |
| JPMorgan Investment Management, Inc.as of 30 Jun 2022 | 1.78m | 1.69% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2022 | 1.30m | 1.23% |
| Credit Suisse Asset Management (Schweiz) AGas of 30 Jun 2022 | 1.20m | 1.13% |
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
